Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.

Lalitha P, Srinivasan M, Manikandan P, Bharathi MJ, Rajaraman R, Ravindran M, Cevallos V, Oldenburg CE, Ray KJ, Toutain-Kidd CM, Glidden DV, Zegans ME, McLeod SD, Acharya NR, Lietman TM.

Clin Infect Dis. 2012 May;54(10):1381-7. doi: 10.1093/cid/cis189. Epub 2012 Mar 23.

2.

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Chen A, Prajna L, Srinivasan M, Mahalakshmi R, Whitcher JP, McLeod S, Lietman TM, Acharya NR.

Am J Ophthalmol. 2008 Mar;145(3):409-412. doi: 10.1016/j.ajo.2007.11.004. Epub 2008 Jan 22.

3.

Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.

Oldenburg CE, Lalitha P, Srinivasan M, Manikandan P, Bharathi MJ, Rajaraman R, Ravindran M, Mascarenhas J, Nardone N, Ray KJ, Glidden DV, Acharya NR, Lietman TM.

Invest Ophthalmol Vis Sci. 2013 Feb 28;54(2):1522-6. doi: 10.1167/iovs.12-11246.

4.

Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315. Epub 2011 Oct 10.

5.

Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.

Ray KJ, Prajna L, Srinivasan M, Geetha M, Karpagam R, Glidden D, Oldenburg CE, Sun CQ, McLeod SD, Acharya NR, Lietman TM.

JAMA Ophthalmol. 2013 Mar;131(3):310-3. doi: 10.1001/jamaophthalmol.2013.1718.

6.

The steroids for corneal ulcers trial: study design and baseline characteristics.

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Arch Ophthalmol. 2012 Feb;130(2):151-7. doi: 10.1001/archophthalmol.2011.303. Epub 2011 Oct 10.

7.

The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, O'Brien KS, Glidden DV, Ray KJ, Oldenburg CE, Zegans ME, Whitcher JP, McLeod SD, Porco TC, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group.

Am J Ophthalmol. 2014 Feb;157(2):327-333.e3. doi: 10.1016/j.ajo.2013.09.025. Epub 2013 Oct 1.

8.

Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.

Sy A, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Ravindran M, Oldenburg CE, Ray KJ, Glidden D, Zegans ME, McLeod SD, Lietman TM, Acharya NR.

Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):267-72. doi: 10.1167/iovs.11-7840.

9.

Nocardia keratitis: clinical course and effect of corticosteroids.

Lalitha P, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J, Priya JL, Sy A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Lietman TM, Acharya NR.

Am J Ophthalmol. 2012 Dec;154(6):934-939.e1. doi: 10.1016/j.ajo.2012.06.001. Epub 2012 Sep 5.

10.

Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.

Oldenburg CE, Lalitha P, Srinivasan M, Rajaraman R, Ravindran M, Mascarenhas J, Borkar DS, Ray KJ, Zegans ME, McLeod SD, Porco TC, Lietman TM, Acharya NR.

Ophthalmic Epidemiol. 2013 Jun;20(3):155-8. doi: 10.3109/09286586.2013.790978. Epub 2013 May 10.

11.

Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.

Sun CQ, Lalitha P, Prajna NV, Karpagam R, Geetha M, O'Brien KS, Oldenburg CE, Ray KJ, McLeod SD, Acharya NR, Lietman TM; Mycotic Ulcer Treatment Trial Group.

Ophthalmology. 2014 Aug;121(8):1495-500.e1. doi: 10.1016/j.ophtha.2014.03.004. Epub 2014 Apr 16.

12.

Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.

Shah VM, Tandon R, Satpathy G, Nayak N, Chawla B, Agarwal T, Sharma N, Titiyal JS, Vajpayee RB.

Cornea. 2010 Jul;29(7):751-7. doi: 10.1097/ICO.0b013e3181ca2ba3.

PMID:
20489580
13.

Visual outcomes in treated bacterial keratitis: four years of prospective follow-up.

McClintic SM, Prajna NV, Srinivasan M, Mascarenhas J, Lalitha P, Rajaraman R, Oldenburg CE, O'Brien KS, Ray KJ, Acharya NR, Lietman TM, Keenan JD.

Invest Ophthalmol Vis Sci. 2014 May 2;55(5):2935-40. doi: 10.1167/iovs.14-13980.

14.

Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial.

Sharma N, Goel M, Bansal S, Agarwal P, Titiyal JS, Upadhyaya AD, Vajpayee RB.

Ophthalmology. 2013 Jun;120(6):1173-8. doi: 10.1016/j.ophtha.2012.11.013. Epub 2013 Feb 15.

PMID:
23415776
15.

Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.

Lalitha P, Prajna NV, Oldenburg CE, Srinivasan M, Krishnan T, Mascarenhas J, Vaitilingam CM, McLeod SD, Zegans ME, Porco TC, Acharya NR, Lietman TM.

Cornea. 2012 Jun;31(6):662-7. doi: 10.1097/ICO.0b013e31823f8ae0.

16.

Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis.

Borkar DS, Fleiszig SM, Leong C, Lalitha P, Srinivasan M, Ghanekar AA, Tam C, Li WY, Zegans ME, McLeod SD, Lietman TM, Acharya NR.

JAMA Ophthalmol. 2013 Feb;131(2):147-53. doi: 10.1001/jamaophthalmol.2013.778.

17.

Association of Biofilm Formation, Psl Exopolysaccharide Expression, and Clinical Outcomes in Pseudomonas aeruginosa Keratitis: Analysis of Isolates in the Steroids for Corneal Ulcers Trial.

Zegans ME, DiGiandomenico A, Ray K, Naimie A, Keller AE, Stover CK, Lalitha P, Srinivasan M, Acharya NR, Lietman TM.

JAMA Ophthalmol. 2016 Apr;134(4):383-9. doi: 10.1001/jamaophthalmol.2015.5956.

PMID:
26846404
18.

Prior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial.

See CW, Srinivasan M, Saravanan S, Oldenburg CE, Esterberg EJ, Ray KJ, Glaser TS, Tu EY, Zegans ME, McLeod SD, Acharya NR, Lietman TM.

Ophthalmic Epidemiol. 2012 Dec;19(6):407-13. doi: 10.3109/09286586.2012.735332.

19.

Early addition of topical corticosteroids in the treatment of bacterial keratitis.

Ray KJ, Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Glidden DV, Oldenburg CE, Sun CQ, Zegans ME, McLeod SD, Acharya NR, Lietman TM.

JAMA Ophthalmol. 2014 Jun;132(6):737-41. doi: 10.1001/jamaophthalmol.2014.292.

20.

Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.

Alexandrakis G, Alfonso EC, Miller D.

Ophthalmology. 2000 Aug;107(8):1497-502.

PMID:
10919897

Supplemental Content

Support Center